1. Alikhan A, Felsten LM, Daly M, Petronic-Rosic V. Vitiligo: A comprehensive overview part I. Introduction, epidemiology, quality of life, diagnosis, differential diagnosis, associations, histopathology, etiology, and work-up. J Am Acad Dermatol [Internet] 2011[ cited 2015 Oct 22];65:473-91. Available from:http://www.ncbi.nlm.nih.gov/ pubmed/ 21839315.
2. Birlea SA, Spritz RA, Noris DA. Vitiligo. In: Goldsmith LA, Katz SI, Gilchrest BA, Paller AS, Leffel DJ, Wolff K,editors. Fitzpatrick's dermatology in general medicine. 8th ed. New York: The MCGraw-Hill companies. 2012. p. 1308-24.
3. Ezzedine K, Lifn HW, Suzuki T, Katayama I, Hamzavi I, Lan CCE, et al.Revised classification/nomenclature of vitiligo and related issues: the vitiligo global issues consensus conference . Pigment Cell Melanoma Res. 2012 May; 25(3): El-13. doi:10.1111/j.l755-148X.2012.00997.x. 3. Yaghoobi R, Omidian M, Bagherani N. Vitiligo: A review of the
published work. Journal of Dermatology. 2011;38:419-31. doi: 10.111 1/j.1346-8138.2010.01139.x.
5. Gawkrodger DJ, Omerod AD, Shaw L, Mauri-sole I, Whitton ME, Watts MJ, et al.Guideline for the diagnosis and management of vitiligo. BJD. 2008; 159: 1051-76. doi: 10.1111/j.1365-2133.2008.08881.x.
6. Vrijman C, Homan MWL, Limpens J, Veen WVD, Wolkerstorfer AW, Terwee CB, et al. Measurement properties of outcome measures for vitiligo. Arch Dermatol [Internet]. 2012 [cited 2015 Oct 24]; 148(11): 1302-9.Available from:http://www.ncbi.nlm.nih.gov/pubmed/ 22986764. 7. Ping TW, KeE GB, lan TS, Kumarasinghe P. Clinical profile of vitiligo
in Singapore: an analysis over a 6-month period. Dermatology bulletin [ Internet]. 2007 [ cited 2015 Oct 26] ; September 18 (2): 19-23. Available from: https://www.nsc.coin.sg/Professional-Education/Documents/NSC- Bulletin-PDF/vol-18-no-2-2007.pdf.
8. Jusuf NK, Meher C. Pola Kelainan Pigmentasi di Poliklinik Kulit dan Kelamin Divisi Kosmetik RSUP H. Adam Malik Medan Tahun 2012-2015. Pertemuan Ilmiah Tahunan XV Ilmu Kesehatan Kulit dan Kelamin. Padang, Indonesia.
9. Rizal Y, Lestari S. Insidensi vitiligo di poliklinik kulit dan kelamin RSUP Dr. M Djamil Padang tahun 2001-2006. MDVI [Internet]. 2008 [cited 2015 Oct 26]; Januari 35 (1): 77. Available from: http://www.perdoski.org /index.php /public /information /mdvi-detail- content/77.
10. Spritz RA. Modern vitiligo genetics sheds new light on ancient disease. J Dermatol. 2013 May; 40(5): 1-15. doi:10.1111/1346-8138.12147.
52
12. Bolander-Gouaille C. Homocysteine, the new marker of disease risk-an overview. Business briefing: European pharmacotherapy. 2005;2-8. doi:10.1.1.199.9952.
13. Selhub J. Homocysteine metabolism. Annu. Rev Nutr. 1999; 19:217-46. doi:0199-9885/99/0715-0217$08.00.
14. Clarke S, Banfield K. S-Adenosylmethionine-dependent methyltransferases. In: Carmel R, Jacobsen DW, editors. Homocysteine in health and disease. Cambridge. Cambridge university press; 2001.p. 63-78
15. Shaker OG, El-Tahlawi SMR. Is there a relationship between homocysteine and vitiligo? A pilot study. BJD. 2008; 159: 720-4. doi: 10.1111/J.1365-2133.2008.08712.X.
16. Juhlin L, Olsson MJ. Improvement of vitiligo after oral treatment with vitamin B12 and folic acid and the importance of sun exposure. Acta Derm Venereol. 1997; 77:460-2. doi:0001-5555.
17. Don P, iuga A, Dacko A, Hardick K. Treatment of vitiligo with broadband ultraviolet B and vitamins. Int J Dermatol [Internet]. 2006 [ cited 2015 Oct 23] ; 45:63-5. Available from: http://www.ncbi. nlm.nih. gov/pubmed/ 16426381.
18. Singh S, Singh U, Pandey SS. Serum folic acid, vitamin B12 and homocysteine levels in Indian vitiligo patients. EDOJ [ Internet]. 2012 June [ cited 2015 Oct 23]; 8(1):1-7. Available from: http :// www. edoj. org.eg/vol008/0801/002/01.htm.
19. Balci DD, Yunden Z, Yenin JZ, Okumus N. Serum homocysteine, folic acid and vitamin B12 levels in vitiligo. EJD. 2009 Jul-Aug; 19 (4): 382- 3. doi:10.1684/ejd.2009.0671.
20. Millington G W. M, Levell N J. Vitiligo: the historical curse of depigmentation. International Journal of Dermatology. 2007;46: 990-5. doi: 10.1111/j. 1365-4632.2007.03195.x.
21. Rahman MH, Amin MZ, Rahman M, Satter MA. A demographic study on vitiligo (sheti) in Bangladesh. Int J Res Med Sci. 2013; 1(2):123-8. doi: 10.5455/2320-6012.ijrms20130517.
22. Puri N, Phil M, Mojamdar M, Ramaiah A. In vitro growth characteristics of melanocytes obtained from adult normal and vitiligo subjects.The journal of investigative dermatology. 1987; 88(4): 434-8. doi: 0022- 202X/87/$03.50.
23. Spritz RA. Six decades of vitiligo genetics: genome-wide studies provide insights into autoimmune pathogenesis. J Invest Dermatol. 2012;132: 268-73. doi: 10.1038/jid.2011.321.
24. Baum S, Barzilai A, Trau H. Vitiligo. In : Shoenfeld Y, Cervera R, Gershwin ME, editors. Diagnostic criteria in autoimmune diseases. Humana press [Internet]. 2008 [cited 2015 Oct 01].p. 353-8. Available from: http://link.springer.com/ book/ 10.1007%2F978-l-60327-285-8
unity. J Invest Dermatol. 2012; 132: 13-5. doi:10.103S /jid.201 1.353. 26. Wang CQF, Cruz-Inigo AE, Fuentes-Duculan J, Moussai D, Gulati N.
Thl7 cells and activated dendritic cells are increased in vitiligo lesions. PLoS One. 2011 April; 6(4): 1-11. doi: 10.1371/journal.pone.0018907 27. Rezaei N, Gavalas NG, Weetman AP, Kemp EH. Autoimmunity as an
aetiological factor in vitiligo. J Eur Acad Dermatol Venereol. 2007; 21: 865-876.doi: 10.1111/J.1468-3083.2007.02228.X.
28. Kemp EH, Emhemad S, Gawkrodger DJ, Weetman AP. Autoimmune disorders-pathogenic aspects. Chapter 14. p. 255-78.
29. Haider N, Islam MS, Al-Maraf A, Shohag MH, Ali R, Rahman GKMM, Hasnat A. Oxidative stress and antioxidant status in vitiligo patients. Dhaka Univ J Pharm Sci. 2010 Dec; 9(2): 103-8. doi: 10.3329/dujps.v9i2.7894.
30. Naini FF, Shooshtari AV, Ebrahimi B, Molaei R. The effect of pseudocatalase/superoxide dismutase in the treatment of vitiligo: a pilot study. J Res Pharm Pract 2012; 1:77-80. doi: 10.4 103/2279-042X. 108375.
31. Shin JW, Nam KM, Choi HR, Huh SY, Kirn SW, Youn SW, et al. Erythrocyte malondialdehyde and glutathione levels in vitiligo patients. Ann Dermatol. 2010; 22(3): 279-83. doi: 10.5021/ad.2010.22.3.279. 32. Amin MZ, Rahman MH, Satter MA. Study of some biochemical
parameters of vitiligo patients in Bangladesh. Bangladesh J Sci Ind Res [ Internet]. 2012 [ cited 2015 Oct 20]; 47(2): 173-86. Available from: . http://www.banglajol.info/index.php/BJSIR /article/view II 1449.
33. Esmaeili B, Rezaee SAR, Layegh P, Afshari JT, Dye P, Karimiani EG, et al . Expression of IL-17 and COX2 gene in peripheral blood leukocytes of vitiligo patients. Iran J Allergy Asthma Immunol [Internet]. 2011 [cited 2015 Oct 1]; 10(2):81-9. Available from: http://www.sid.ir /en/VEWSSID/J_pdf/943201 10202.pdf.
34. Glassman SJ. Vitiligo, reactive oxygen species and T-cells. Clin Sci. 2011; 120: 99-120.doi: 10.1042/CS20090603.
35. Kamel N, Sobhy N, Kamal H, Ismail M. A comparative study of oxidant-antioxidant status in blood and tissue in vitiligo patients. EDOJ [Internet].2010 [cited 2015 Oct 1] ; 6(2): 1-10. Available from: http://www.edoj.org.eg/vol006/0602/002/paper.pdf.
36. Faria AR, Mira MT, Tarle RG, Castro CCS, Dellatore G. Vitiligo-part2 classification, histopathology and treatment. An Bras Dermatol. 2014;89(5):784-90.doi: 10.1590/abdl806-4841.20142717.
54
38. Brazelli V, Antoninetti M, Palazzini S, Barbagallo T, De Silvestri A, Borroni G. Critical evaluation of the variants influencing the clinical response of vitiligo: study of 60 cases treated with ultraviolet B narrow band phototherapy. J Eur Acad Dermatol Venereol. 2007;21:1369-74. doi: 10.1111/j.1468-3083.2007.02278.x.
39. Taieb A, Morice-Picard F, Jouary T, Ezzedine K, Cario^Andre M, Gauthier Y. Segmental vitiligo as the possible expression of cutaneous somatic mosaicism: implications for common non-segmental vitiligo. Pigment Cell Melanoma Res. 2008; 21:646-52. doi: 10.1111/j. 1755- 148X.2008.00511.x.
40. Hann S, Chang J, Lee H, Kim S. The classification of segmental vitiligo on the face. Yonsei Med J [Internet]. 2000 [ cited 2015 Oct 22]; 41(2): 209-12. Available from:http://www.ncbi.nlm.nih.gov/pubmed/10817021. 41. Bhor U, Pande S. Scoring systems in dermatology. Indian J Dermatol
Venereol Leprol [serial online] 2006 [cited 2015 Nov 10];72:315-21. Available from: http://www.ijdvl. com/text.asp?2006/72/4/315/26722. 42. Alghamdi KM, Kumar A, Taieb A, Ezzedine K. Assessment methods for
the evaluation of vitiligo. JEADV. 2012;1-9. doi: 10.1111/j. 1468- 3083.2012.04505.x.
43.Taieb A, Picardo M. The definition and assessment of vitiligo: a consensus report of the Vitiligo European Task Force. Pigment Cell Res.2007; 20:27-35. doi: 10.1111/j.1600-0749.2006.00355.
44. Kawakami T, Hashimoto T. Disease severity indexes and treatment evaluation criteria in vitiligo. Dermatol Res Pract. 2011; 1-3. doi: 10.1155 72011/750342.
45. Al-mutairi N, Nour-Eldin O. Vitiligo treatment update. GJDV [Internet]. 2003 Oct [cited 2015 Oct 23] ;10 (2): 1-13. Available from: http://www. gulfdermaj ournal. com/pdf/2003 -10/1 .pdf.
46. Bordere AC, Lambert J, Geel NV. Current and emerging therapy for the management of vitiligo. Clin Cosmet Investig Dermatol [Internet]. 2009[cited 2015 Oct 25] ; 2: 15-25. Available from: http://www. ncbi .nlm. nih.gov/pmc/articles/PMC3047938/.
47. Felsten L, Alikhan A, Petronic-Rosic V. Vitiligo:A comprehensive overview part II: Treatment options and approach to treatment. J Am Acad Dermatol [Internet]. 2011[ cited 2015 Oct 22];65:493-514. Available from: http://www .ncbi.nlm. nih.gov/pubmed/21839316.
48. Clarke R. Lowering blood homocysteine with folic acid base supplements: meta-analysis of randomised trials. BMJ [Internet].
1998[cited 2015 Oct 2]; 894-8. Available from: http://www. ncbi.nlm.nih.gov/pmc/articles/PMC28491/pdt7894.pdf.
49. Yasar A, Gunduz K, Onur E, Calkan M. Serum homocysteine, vitamin B12, folic acid, levels and methylenetetrahtdrofolate reductase (MTHFR) gene polymorphism in vitiligo. Dis Markers. 2012; 33:85-9. doi: 10.3233/DMA-2012-0908..
50. Andre's E, Loukili NH, Noel E, Kaltenbach G, Abdelgheni MB, Perrin AE, et al. Vitamin B12 (cobalamin) deficiency in elderly patients. CMAJ [Internet]. 2004 [cited 2015 Oct 1] ; 17(3): 251-9. Available from:http://www.researchgate.net/profile/Frederic_Maloisel/publicatio n/8421627_Vitamin_B12_(cobalamin)_deficiency_in_elderly_patients /links/OOb49 52289e7cc6179000000.pdf.
51. Hustad S, Ueland PM, Vollset SE, Zhang Y, Bj0rke-Monsen AL, Schneede J. Riboflavin as a determinant of plasma total homocysteine: effect modification by the rnethylenetetrahydrofolate reductase C677T polymorphism. Clin Chem [ Internet]. 2000 [ cited 2015 Oct 25]; May 46 (8): 1065-71. Available from: http://www .clinchem . org/content/46/8/1065. Long.
52. Ubbink JB, Vermaak WJH, Merwe AVD, Becker PJ. Vitamin B- 12,vitamin b-6, and folate nutritional status in men withhyperhomocysteinemia. Am J Clin Nutr [Internet]. 1993 [ cited 2015 Oct23] ; 57: 47-53. Availabe from: http://ajcn. nutrition, org/ content' /57/l/47.1ong.
53. Bailey LB, Gregory JF. Folate metabolism and requirements. J. Nutr [Internet]. 1999 [cited 2015 Oct 27]; 129: 779-82. Available from: http://jn.nutrition.org/content/129/4/779.full.pdf+html.
54. Sabry HH, Sabry JH, Hashim HM. Serum levels of homocysteine, vitamin B12, and folic acid in vitiligo. Egypt J Dermatol Venerol [Internet] 2014 [cited 2015 Nov 27];34:65-9. Available from: http://www.ejdv.eg.net/text.asp?2014/34/l/65/137315.
55. Silverberg JI, Silverberg NB. Serum homocysteine as a biomarker of vitiligo vulgaris severity: A pilot study. J Am Acad Dermatbl. 2011. 64(2): 445-7. doi: 10.1016/j,jaad.2010.08.025.
56. Ghalamkarpour F Jafarian Z, Einollahi H, Younespour S. Homocysteine: is it a biomarker for vitiligo? Journal of pigmentary disorders. 2015; 2(4): 1-4. doi: 10.4172/2376-0427.1000172.
57. Yasar A, Gunduz K, Onur E, Calkan M. Serum homocysteine, vitamin B12, folic acid levels and methylenetetrahydrofolate reductase (MTHFR) gene polymorphism in vitiligo. Disease markers. 2012; 33: 85-9. Doi: 10.3233/DMA-2012-0908.
58. Yu H, Chang K, Yu C, Li H, Wu M, Wu C,et al. Alterations in IL-6, IL-8, GM-CSF, TNF-a, and IFNy release by peripheral mononuclear cells in patients with active vitiligo. J invest Dermatol. 1997.108: 527-9. doi: 10.111 l/1523-1747.ep12289743.
59. Becatti M, Prigano F, Fiorillo, Pescitelli L, Nassi P, Lotti T, Taddei N.The involvement of Smac/DIABLO, p53,NF-kB, and MAPK pathways in apoptosis of keratinocytes from perilesional vitiligft skin: protective effects of curcumin and capsaicin. Antioxidants & Redox Signaling. 2010; 13(9): 1309-21. doi: 10.1089/ars.2009.2779.
60. Silverberg NB. The Epidemiology of Vitiligo. Curr Derm Rep. 2015 Januari; 4:36–43.doi: 10.1007/s13671-014-0098-6.
56 62. Jha BN. Assessment of Prevalence of Clinical and Sociodemographic
Study of Vitiligo in Janaki Medical College, Nepal. 2016 Februari;ARJLS. 2(2):1 – 4. ISSN: 2455-3549.
63. Wang X, et al. Prevalence and Clinical Profile of Vitiligo in China: A Community based Study in Six Cities. Acta Derm Venereol 2013; 93: 62–5. doi: 10.2340/00015555-1397.
64. Patil S, Gautam M, Nadkarni N, Saboo N, Godse K, Setia MS. Gender Differences in Clinicoepidemiological Features of Vitiligo: A Cross-Sectional Analysis. ISRN Dermatology. 2014 Feb;1-6. doi: 10.1155/2014/186197.
65. Zaki AM, Abdo HM, Ibrahim IM, Ibrahim AEKI. Serum homocysteine and vitiligo. The gulf journal of dermatology and venereology[Internet]. 2014[ cited 2015 Nov 29] ; 21(2): 15-20. Availble from: https://www. google.com/url?sa=t&rct=j&q=&esrc=s&source=web&cd=3&ved=0ah UKEwjzy8p1cnKAhVBBY4KHQnjB1EQFggrMAI&url=http%3A%2F %2Fwww.gulfdermajournal.com%2Fpdf%2F201410%2F2.pdf&usg=AF QjCNGXyvhhvl6trAe0SHRVAImXn0Yi1g&sig2=5MUvJNMVGIU_eS 1rBkBO7A&cad=rj
66. Koehler KM, Baum RG, Gary PJ, Allen RH, Stabler SP, Rimm EB. Association of folate intake and serum homocysteine in elderly persons according to vitamin supplementation and alcohol use. Am J Clin Nutr. 2001 March ; 73:628–37. PMID:11237942.
67. Agarwal S, Mendiratta V, Chander R, Jain A, Yadav P. Study of serum levels of Vitamin B, folic acid, and homocysteine in vitiligo. Pigment Int 2015;2:76-80. doi: 10.4103/2349-5847.172777